Sign in
Taking people in United StatesNo phase

Magnesium and melatonin supplement for sleep in people with nighttime leg cramps

Tests a magnesium and melatonin supplement for sleep in adults with nighttime leg cramps.

Key facts

Who runs it
StudySetGo
Where
Atlanta, Birmingham, Charleston, Charlotte, Little Rock, Nashville, and Palm Beach Gardens, United StatesSee the 7 sites
Trial code
Registry title
The Effect of a Daily Magnesium and Melatonin Supplement on Sleep Quality in People With Nighttime Leg Cramps
Status
Recruiting
People taking part
50 people, planned
Started
10 Oct 2026
Expected to end
10 Sept 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Magnesium and melatonin based multi-ingredient dietary supplementation
  • Placebo
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in Florida who sleep poorly because of nighttime leg cramps. It tests a magnesium and melatonin supplement against a placebo (a dummy pill).

Age
40 to 75 years
Sex
All sexes can join
Disease stage
Poor sleep quality you report yourself (PSQI >5), and nighttime leg cramps averaging ≥4 episodes per fortnight.
Earlier treatment
You cannot join if you use melatonin, magnesium, or other supplements for sleep or leg cramps now or within 4 weeks before the start. You cannot join if you take any prescription medicine now.

Main reasons for not taking part

  • A diagnosed sleep disorder, such as sleep apnoea, restless legs syndrome or insomnia disorder
  • A known other cause of the leg cramps, such as blood vessel, nerve, kidney or thyroid problems
  • Current or past heart and blood vessel disease, diabetes, autoimmune, gut, nerve, liver or kidney disease, or severe mental illness
  • Cancer, unless in confirmed remission with all treatment finished
  • Pregnant, breastfeeding or planning pregnancy; shift work or irregular sleep; not living permanently in Florida

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Adults aged 40-75 years
  • Self-reported poor sleep quality (PSQI >5) at screening
  • Self-reported nocturnal leg cramp averaging ≥4 episodes per fortnight at screening
  • Capacity to understand and provide electronic informed consent
  • Willing to wear an Oura Ring wearable device continuously throughout the study period
  • Access to a smartphone/tablet with iOS 15 or higher and Android 9 or higher and willing to install and use the Oura and Trialflare applications
  • Be a resident of and permanently living in Florida with no planned travel across more than one time zone for at least 1 night during the study period

Who cannot take part

  • Current use of any prescription medication
  • Any current or prior diagnosis of:
  • Diagnosed sleep disorder (e.g. obstructive sleep apnoea, restless legs syndrome, insomnia disorder)
  • Known or suspected secondary cause of nocturnal leg cramps (e.g. peripheral vascular disease, neurological condition, renal impairment, thyroid disorder)
  • Cancer or malignancy of any kind (prior malignancy is not exclusionary if the participant is in confirmed remission and has completed all treatment)
  • Cardiovascular disease (e.g. hypertension, coronary artery disease, heart failure, arrhythmia, stroke, peripheral vascular disease)
  • Autoimmune disorder (e.g. rheumatoid arthritis, lupus, multiple sclerosis)
  • Gastrointestinal disorder (e.g. IBS, malabsorption syndromes)
  • Neurological disorder (e.g. epilepsy, Parkinson's disease, dementia)
  • Hepatic or renal impairment
  • Diabetes mellitus (type 1 or type 2)
  • Severe psychiatric disorder (e.g. schizophrenia, bipolar disorder)
  • Known hypersensitivity or allergy to any ingredient in the active or placebo product
  • Current or recent (within 4 weeks of randomisation) use of melatonin, magnesium, or other supplements specifically taken for sleep or leg cramps or listed as an ingredient of the intervention supplement
  • Myasthenia Gravis
  • Rotating shift work or irregular sleep patterns
  • Current participation in another interventional clinical trial
  • Inability to comply with study procedures or remote visit schedule
  • Breastfeeding, pregnant, or planning to become pregnant during the study period

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 75 years old?

Where in United States

  • Remote participation (home-based, no site visits)Atlanta, United StatesContact: Christopher Koscien, PhDTaking people
  • Remote participation (home-based, no site visits)Birmingham, United StatesContact: Christopher Koscien, PhDTaking people
  • Remote participation (home-based, no site visits)Charleston, United StatesContact: Christopher Koscien, PhDTaking people
  • Remote participation (home-based, no site visits)Charlotte, United StatesContact: Christopher Koscien, PhDTaking people
  • Remote participation (home-based, no site visits)Little Rock, United StatesContact: Christopher Koscien, PhDTaking people
  • Remote participation (home-based, no site visits)Nashville, United StatesContact: Christopher Koscien, PhDTaking people
  • Remote participation (home-based, no site visits)Palm Beach Gardens, United StatesContact: Tom JamesonTaking people

About the trial

What the trial wants to find out

Participants are being invited to take part in a research study. Before deciding whether to take part, it is important for participants to understand why the research is being done and what it will involve.

Read full original descriptionShow less

Purpose: This study will investigate whether a multi-ingredient nutritional supplement containing magnesium and melatonin can improve sleep quality in adults who experience disrupted sleep due to nighttime leg cramps.

What participation involves: Participation lasts 8 weeks. Participants will be randomly assigned to take either the nutritional supplement or a placebo (inactive look-alike) every night before bed for 6 weeks. Participants will wear an Oura Ring wearable device on one finger continuously for 8 weeks throughout the study and complete short questionnaires using a smartphone app. The Oura Ring and study supplement will be sent to the participant's home address. Participants will never need to travel to a research centre; all contact with the research team will be by video call, phone, messaging, or email.

How long: Total involvement will be 8 weeks, made up of a 2-week baseline period and a 6-week supplementation period. Each day, participants will complete a short app-based questionnaire (approximately 1 minute). At the end of weeks 2, 4, 6, and 8, participants will complete additional app-based questionnaires (approximately 10 minutes).

The 2 groups in the trial

  • Magnesium and melatonin based multi-ingredient dietary supplementTreatment being tested

    Treatment: Magnesium and melatonin based multi-ingredient dietary supplementation

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Investigation Into the Effect of a Daily Magnesium and Melatonin Based Multi-Ingredient Dietary Supplement on Sleep Quality in Individuals With Self-Reported Nighttime Leg Cramps.
Plain-language title
Magnesium and melatonin supplement for sleep in people with nighttime leg crampsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07651514, who can take part
Record updated
2 November 2026